AMPH Amphastar Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1297184 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.1%
TTM net income YoY-11.3%
TTM EPS YoY-3.5%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR-9.9%
Margins
Gross margin46.8%
Operating margin18.7%
Net margin13.3%
FCF margin18.6%
EBITDA margin22.4%
Returns
ROE12.4%
ROA5.9%
ROIC (approx.)8.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets52.4%
Debt / equity0.75x
Current ratio3.32x
Interest coverage5.25x
Cash quality & payout
Operating cash flow / net income1.77x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $719.89M | $731.97M |
| Cost of revenue | $363.83M | $358.11M |
| Gross profit | $356.06M | $373.86M |
| R&D expense | $85.84M | $73.91M |
| SG&A expense | $85.92M | $56.72M |
| Operating income | $140.40M | $205.42M |
| Interest expense | $25.48M | $30.34M |
| Pretax income | $123.62M | $189.76M |
| Income tax | $25.53M | $29.67M |
| Net income | $98.09M | $159.52M |
| EBITDA | $172.05M | $233.67M |
| EPS (basic) | 2.10 | 3.29 |
| EPS (diluted) | 2.03 | 3.06 |
| Weighted avg. shares (diluted) | 48.22M | 52.06M |
| Balance sheet | ||
| Cash & equivalents | $170.18M | $151.84M |
| Short-term investments | $112.64M | $70.04M |
| Receivables | $143.56M | $136.29M |
| Inventory | $176.89M | $153.74M |
| Current assets | $636.02M | $534.07M |
| PP&E, net | $310.57M | $297.35M |
| Goodwill | $3.40M | $3.05M |
| Intangibles | $533.34M | $558.39M |
| Total assets | $1.63B | $1.58B |
| Current liabilities | $158.16M | $173.76M |
| Short-term debt | $1.64M | $234,000 |
| Long-term debt | $608.75M | $601.63M |
| Total debt | $610.39M | $601.86M |
| Total liabilities | $840.49M | $845.17M |
| Shareholders' equity | $788.80M | $732.30M |
| Net debt | $440.21M | $450.02M |
| Shares outstanding | 45.65M | 47.62M |
| Cash flow statement | ||
| Operating cash flow | $156.12M | $213.39M |
| Capital expenditure | $34.88M | $41.04M |
| Free cash flow | $121.23M | $172.34M |
| Investing cash flow | -$70.33M | -$124.93M |
| Financing cash flow | -$67.42M | -$80.95M |
| Depreciation & amortization | $31.65M | $28.25M |
| Stock-based compensation | $27.28M | $24.37M |
| Share buybacks | $75.59M | $85.46M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.